Share repurchase programme Silkeborg, 2016-09-09 08:15 CEST

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Share repurchase programme

Silkeborg, 2016-09-09 08:15 CEST (GLOBE NEWSWIRE) -- The share buy-back programme runs from 01 July 2016 to 31 December 2016. In this period Jyske Bank will acquire shares with a value of up to DKK 1.0 billion, cf. company announcement No. 48/2016 of 18 August 2016, where the original share buy-back programme of DKK 500 million got increased with a total amount of DKK 500 million. The share buy-back programme is initiated and structured in compliance with the EU Commission Regulation No. 2273/2003 of 22 December 2003 (the so-called Safe Harbour Regulative for share buy-back programmes), and from 03 July 2016 in accordance with the EU Commission Regulation No. 596/2014 of 16 April 2014 on market abuse (Market Abuse Regulation), which ensures that Jyske Bank is protected against violation of insider legislation in relation to the share buy-back programme.

Since the announcement as of 01 July 2016, the following transactions have been made under the program:

  Number of shares Average purchase price Transaction value in DKK
Accumulated, last announcement 825,000 283.02 233,490,172
02 September 2016 30,000 323.53 9,706,035
05 September 2016 30,000 325.23 9,756,759
06 September 2016 30,000 319.29 9,578,670
07 September 2016 30,000 316.41 9,492,213
08 September 2016 30,000 317.25 9,517,530
Accumulated under the programme 975,000 288.76 281,541,379

With the transactions stated above, Jyske Bank now owns a total of 3,617,740 of treasury shares, excluding investments made on behalf of customers and shares held for trading purposes, corresponding to 3.81% of the share capital.

In accordance with the EU Commission Regulation No. 596/2014, transactions related to the share buy-back programme are presented in detailed form in the spread sheet attached to this company announcement.

Yours faithfully,

Jyske Bank

Any questions in regards to this announcement may be addressed to Trine Lysholt Nørgaard, Director, Head of Investor Relations, on tel. +45 89 89 64 29.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 250

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 88

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 273

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 241

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 322

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 393

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 47

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
IS: Thai Approval Opens New Sarcoma Treatment Path"> Continue Reading